0001562180-22-007082.txt : 20221005 0001562180-22-007082.hdr.sgml : 20221005 20221005174023 ACCESSION NUMBER: 0001562180-22-007082 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221003 FILED AS OF DATE: 20221005 DATE AS OF CHANGE: 20221005 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Biohaven Pharmaceutical Holding Co Ltd. CENTRAL INDEX KEY: 0001689813 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] STATE OF INCORPORATION: D8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41477 FILM NUMBER: 221296616 BUSINESS ADDRESS: STREET 1: 215 CHURCH STREET CITY: NEW HAVEN STATE: CT ZIP: 06510 BUSINESS PHONE: 203-404-0410 MAIL ADDRESS: STREET 1: 215 CHURCH STREET CITY: NEW HAVEN STATE: CT ZIP: 06510 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Biohaven Ltd. CENTRAL INDEX KEY: 0001935979 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: D8 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 215 CHURCH STREET CITY: NEW HAVEN STATE: CT ZIP: 06510 BUSINESS PHONE: 203-404-0410 MAIL ADDRESS: STREET 1: 215 CHURCH STREET CITY: NEW HAVEN STATE: CT ZIP: 06510 FORMER COMPANY: FORMER CONFORMED NAME: Biohaven Research Ltd. DATE OF NAME CHANGE: 20220629 4 1 primarydocument.xml PRIMARY DOCUMENT X0306 4 2022-10-03 false 0001935979 Biohaven Ltd. BHVN 0001689813 Biohaven Pharmaceutical Holding Co Ltd. C/O BIOHAVEN PHARMACEUTICALS, INC. 215 CHURCH STREET NEW HAVEN CT 06510 false false true false Common Shares 2022-10-03 4 J false 35839857.00 0.00 A 35839857.00 D Common Shares 2022-10-03 4 J false 35839857.00 0.00 D 0.00 D On October 3, 2022, in connection with the distribution by Biohaven Pharmaceutical Holding Company Ltd. ("RemainCo") of the outstanding common shares of the Issuer ("Common Shares") pursuant to the Separation and Distribution Agreement, dated May 9, 2022, between RemainCo and the Issuer, the Issuer issued to RemainCo 35,839,857 Common Shares (the "Issuance"). On October 3, 2022, immediately following the Issuance, all of the outstanding common shares of the Issuer held by RemainCo were distributed by way of a pro rata distribution to RemainCo's shareholders (the "Distribution"). As a result of the Distribution, RemainCo no longer beneficially owns any common shares of the Issuer and consequently is no longer subject to the requirements of Section 16 of the Exchange Act with respect to the Issuer. /s/ George Clark, Attorney-in-Fact 2022-10-05